William Zigrang
Endocrinology, Diabetes & Metabolism · Burlingame, CANPI 1821002783
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,600 of the $11,945 with a category attached, or 63.6%. Lilly USA, LLC accounts for 67.2% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2020 at $4,540 and has fallen 96.0% since, to $183 in 2024.
Across 140 payments — averaging $85.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$8K
- Amgen$618
- Novo Nordisk$513
- Sanofi-aventis U.S. LLC$353
- Boehringer Ingelheim$346
- AstraZeneca$275
- plus $2K from 16 others
What the payments were for
- Speaking & faculty fees$7,60064%
- Food & beverage$4,31836%
- Education$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 29 | $8,032 |
| Amgen(2 entities) | 15 | $618 |
| Novo Nordisk | 17 | $513 |
| Sanofi-aventis U.S. LLC | 14 | $353 |
| Boehringer Ingelheim | 8 | $346 |
| AstraZeneca(2 entities) | 11 | $275 |
| Abbott | 5 | $274 |
| Mannkind Corporation | 4 | $236 |
| Zealand Pharma US, Inc. | 1 | $189 |
| Eli Lilly | 1 | $173 |
| Janssen Scientific Affairs, LLC | 3 | $136 |
| Johnson & Johnson | 9 | $132 |
| Corcept Therapeutics | 3 | $129 |
| Merck | 4 | $117 |
| Insulet Corporation | 6 | $109 |
| Esperion Therapeutics, Inc. | 1 | $102 |
| Regeneron Healthcare Solutions, Inc. | 3 | $85 |
| Radius Health, Inc. | 2 | $40 |
| Vivus LLC | 1 | $24 |
| Shire North American Group Inc | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $23 |
| Medtronic | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,945 in reported general payments places this provider in the 80th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $4,495 |
| Metformin Hcl ErMetformin Hcl | 13 | $79 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Burlingame
- David KlonoffBurlingame$74K
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.